Cargando…

Clinical trials with MRNA electroporated dendritic cells for stage III/IV melanoma patients

Detalles Bibliográficos
Autores principales:	Wilgenhof, Sofie, Corthals, Jurgen, Heirman, Carlo, Neyns, Bart, Thielemans, Kris
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649544/ http://dx.doi.org/10.1186/2051-1426-3-S2-P211

Ejemplares similares

Phase II study of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with Ipilimumab in patients with pretreated advanced melanoma
por: Thielemans, Kris, et al.
Publicado: (2014)

Characterization of CD8(+) T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)
por: Benteyn, Daphné, et al.
Publicado: (2013)

TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
por: De Keersmaecker, Brenda, et al.
Publicado: (2020)

AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells
por: Maenhout, Sarah K., et al.
Publicado: (2014)

Overcoming HLA restriction in clinical trials: Immune monitoring of mRNA-loaded DC therapy
por: Van Nuffel, An M.T., et al.
Publicado: (2012)

S43. Dendritic cell vaccination combined with CTLA4 blockade
por: Thielemans, K, et al.
Publicado: (2014)

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports
por: Wilgenhof, Sofie, et al.
Publicado: (2012)

mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic
por: Van Lint, Sandra, et al.
Publicado: (2013)

P18-03. Dendritic cell-based immune therapy against HIV-1
por: Gruters, RA, et al.
Publicado: (2009)

Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
por: Benteyn, Daphné, et al.
Publicado: (2013)

Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma
por: Markovic, Svetomir N, et al.
Publicado: (2006)

Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients
por: Seremet, Teofila, et al.
Publicado: (2016)

Skin-derived tumor specific T cells predict clinical outcome in dendritic cell vaccination studies in both stage III and IV melanoma patients
por: Aarntzen, EHJG, et al.
Publicado: (2010)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

Intranodal administration of mRNA encoding nucleoprotein provides cross-strain immunity against influenza in mice
por: Joe, Patrick Tjok, et al.
Publicado: (2019)

Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production
por: Broos, Katrijn, et al.
Publicado: (2019)

CD8α(+) and CD8α(−) Subclasses of Dendritic Cells Direct the Development of Distinct T Helper Cells In Vivo
por: Maldonado-López, Roberto, et al.
Publicado: (1999)

Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
por: Schreuer, Max, et al.
Publicado: (2016)

Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity
por: Van der Jeught, Kevin, et al.
Publicado: (2014)

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon
por: Broos, Katrijn, et al.
Publicado: (2016)

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
por: Bialkowski, Lukasz, et al.
Publicado: (2016)

Circulating dendritic cell levels identify high-risk stage II-III melanoma patients: a potential role as additional prognostic marker
por: Stucci, Stefania, et al.
Publicado: (2015)

Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

Symptomatic Histologically Proven Necrosis of Brain following Stereotactic Radiation and Ipilimumab in Six Lesions in Four Melanoma Patients
por: Du Four, Stephanie, et al.
Publicado: (2014)

Effects of Ipilimumab on expanded tumor infiltrating lymphocytes in patients with stage IV malignant melanoma
por: Bjørn, Jon, et al.
Publicado: (2013)

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
por: Bol, Kalijn F, et al.
Publicado: (2015)

Characterization and Clinical Utility of BRAF(V600) Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma
por: Rutkowski, Piotr, et al.
Publicado: (2021)

Immune biomarker correlates from a Phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)
por: Lapointe, Réjean, et al.
Publicado: (2015)

A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
por: Long, Georgina V, et al.
Publicado: (2015)

A pilot study of Ipilimumab in patients with stage IV melanoma receiving palliative radiation therapy
por: Knox, Susan, et al.
Publicado: (2014)

Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma
por: Chevolet, Ines, et al.
Publicado: (2015)

Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation
por: Fostier, Karel, et al.
Publicado: (2018)

Pathogenic germline variants are associated with poor survival in stage III/IV melanoma patients
por: Aoude, Lauren G., et al.
Publicado: (2020)

Association between durable response (DR) and overall survival (OS) in patients with unresected stage IIIb-IV melanoma treated with Talimogene Laherparepvec (T-VEC) in the Phase III OPTiM trial
por: Kaufman, Howard L, et al.
Publicado: (2014)

Influence of resuscitation status on the performance of APACHE III, APACHE IV and SAPS III
por: Keegan, MT, et al.
Publicado: (2011)

A Phase III study (CheckMate 238) of adjuvant immunotherapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage IIIb/c or stage IV melanoma (MEL) in patients (pts) at high risk for recurrence
por: Weber, Jeffrey, et al.
Publicado: (2015)

Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients
por: Morse, Michael A, et al.
Publicado: (2015)

Increased tryptophan, but not increased glucose metabolism, predict resistance of pembrolizumab in stage III/IV melanoma
por: Oldan, Jorge D., et al.
Publicado: (2023)

Electroporated Antigen-Encoding mRNA Is Not a Danger Signal to Human Mature Monocyte-Derived Dendritic Cells
por: Hoyer, Stefanie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8m6rgm5u067urkrs7gh1mnld64